CA3069197A1 - Recombinant uricase enzyme - Google Patents

Recombinant uricase enzyme Download PDF

Info

Publication number
CA3069197A1
CA3069197A1 CA3069197A CA3069197A CA3069197A1 CA 3069197 A1 CA3069197 A1 CA 3069197A1 CA 3069197 A CA3069197 A CA 3069197A CA 3069197 A CA3069197 A CA 3069197A CA 3069197 A1 CA3069197 A1 CA 3069197A1
Authority
CA
Canada
Prior art keywords
uricase
recombinant mutant
substituted
subject
utilis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069197A
Other languages
English (en)
French (fr)
Inventor
Aditi R. Deshpande
Danica Grujic
Sridhar Govindarajan
Mark Welch
Original Assignee
ALLENA PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALLENA PHARMACEUTICALS Inc filed Critical ALLENA PHARMACEUTICALS Inc
Publication of CA3069197A1 publication Critical patent/CA3069197A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3069197A 2017-07-07 2018-07-06 Recombinant uricase enzyme Pending CA3069197A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762529726P 2017-07-07 2017-07-07
US62/529,726 2017-07-07
US201862678511P 2018-05-31 2018-05-31
US62/678,511 2018-05-31
PCT/US2018/041015 WO2019010369A1 (en) 2017-07-07 2018-07-06 RECOMBINANT ENZYME URICASE

Publications (1)

Publication Number Publication Date
CA3069197A1 true CA3069197A1 (en) 2019-01-10

Family

ID=64951239

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069197A Pending CA3069197A1 (en) 2017-07-07 2018-07-06 Recombinant uricase enzyme

Country Status (8)

Country Link
US (2) US20200308534A1 (https=)
EP (1) EP3655527A4 (https=)
JP (2) JP2020530282A (https=)
CN (1) CN111373034A (https=)
AU (1) AU2018297309A1 (https=)
CA (1) CA3069197A1 (https=)
IL (1) IL271813A (https=)
WO (1) WO2019010369A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN114480320B (zh) * 2022-02-28 2024-01-16 复旦大学 重组夜猴尿酸酶及其应用
CN118497162B (zh) * 2024-05-24 2025-05-16 广东少和生物科技有限公司 黑酵母菌尿酸氧化酶及其突变体和应用
CN119876071B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 低免疫原性的高活性人源尿酸氧化酶突变体
CN119876069B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3462313B2 (ja) * 1995-08-24 2003-11-05 キッコーマン株式会社 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20050049166A1 (en) * 2003-08-29 2005-03-03 Huang Tsao-Chin Clare Enzyme-based cleaning composition and method of use
GB0326676D0 (en) * 2003-11-15 2003-12-17 Astrazeneca Ab Protein
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
WO2006012438A2 (en) 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
CN101390969A (zh) * 2008-11-03 2009-03-25 中国人民解放军军事医学科学院生物工程研究所 降低血液中尿酸浓度的药物
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
DE112011100467B4 (de) * 2010-02-05 2018-07-12 New England Biolabs, Inc. Restriktionsendonukleasen mit hoher Genauigkeit
CN102586315A (zh) * 2012-02-21 2012-07-18 章泽人 一种低尿酸分泌量益生菌及其制备方法
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN104342415A (zh) * 2014-07-08 2015-02-11 吉林省金梓源生物科技有限公司 一种重组尿酸酶的制备方法
AR101504A1 (es) * 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
CN106554948B (zh) 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
KR20180120753A (ko) 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN107308452A (zh) * 2017-05-29 2017-11-03 钟术光 一种稳定生物活性材料的组合物的制备方法
GB201713732D0 (en) * 2017-08-25 2017-10-11 Alta Innovations Ltd Tat expression system
CN109223707B (zh) 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
CN109846909B (zh) * 2019-01-31 2022-03-22 武汉康复得生物科技股份有限公司 可在肠道中催化尿酸降解的组合物及其制备方法和应用
KR20250041198A (ko) * 2019-05-10 2025-03-25 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소

Also Published As

Publication number Publication date
EP3655527A1 (en) 2020-05-27
EP3655527A4 (en) 2021-06-16
US20200071681A1 (en) 2020-03-05
JP2023126877A (ja) 2023-09-12
CN111373034A (zh) 2020-07-03
WO2019010369A1 (en) 2019-01-10
US20200308534A1 (en) 2020-10-01
IL271813A (en) 2020-02-27
JP2020530282A (ja) 2020-10-22
AU2018297309A1 (en) 2020-01-30
US10815461B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
US10815461B2 (en) Recombinant uricase enzyme
BR112014015803B1 (pt) Arginase peguilada e composição farmacêutica para tratamento de uma doença relacionada com arginase
JP7404510B2 (ja) ポリエチレングリコール修飾尿酸オキシダーゼ
US20220298215A1 (en) Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein
CN105062987A (zh) 重组人/狒狒嵌合尿酸酶蛋白及其制备方法
WO2026082147A1 (zh) 一种双靶点受体激动剂融合蛋白及其应用
CN114075296A (zh) 一种多功能变体蛋白及其融合蛋白
CN114438048B (zh) 尿酸氧化酶制剂及其应用
CN102757945B (zh) 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN119613503A (zh) 可抑制类mers冠状病毒感染的多肽及其应用
KR20250102005A (ko) 선천성 수크라제-이소말타제 결핍증을 치료하기 위한 방법 및 조성물
CN105693864A (zh) 一种三聚体trail蛋白及其应用
CN117603934B (zh) 一种尿酸酶的纯化方法
WO2019173293A1 (en) Affinity purification of glycoside-cleaving enzymes
CN102532300B (zh) 干扰素α突变体及其聚乙二醇衍生物
CN101265467A (zh) 一种定点引入非天然氨基酸的突变尿酸氧化酶及其制备方法
JP2021080171A (ja) 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法
US20220378886A1 (en) Methods of treating hyperoxaluria
KR20260028797A (ko) 요산 산화효소 및 이의 페길화 접합체의 안정제 및 그 약학적 용도
WO2025155915A1 (en) Methods and compositions for treating congenital sucrase-isomaltase deficiency
CN120210253A (zh) 基于nadh代谢的线粒体修复因子及其在哮喘治疗中的应用
TW202029967A (zh) 用於治療用途之經工程改造之靈長目動物胱胺酸/半胱胺酸降解酵素
CN105441453A (zh) 一种聚乙二醇修饰trail重组蛋白的制备方法
CN102584980A (zh) 干扰素α突变体及其聚乙二醇衍生物
CN102558337A (zh) 干扰素α突变体及其聚乙二醇衍生物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230704